HITE Hedge Asset Management’s Editas Medicine EDIT Stock Holding History

HITE Hedge Asset Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-21,046	Closed	-$559K	–	154
2021 Q4	$559K	Hold	21,046	–	–	0.06%	125
2021 Q3	$865K	Hold	21,046	–	–	0.11%	107
2021 Q2	$1.19M	Buy	+21,046	New	+$777K	0.17%	93

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

HITE Hedge Asset Management's EDIT Position: Q1 2022 in Review

HITE Hedge Asset Management sold out of Editas Medicine (EDIT) in Q1 2022, closing a stake of 21,046 shares — an estimated $559K sold.

HITE Hedge Asset Management first reported a position in EDIT in Q2 2021 and held it in 3 quarters. The position peaked at $1.19M in Q2 2021. 256 funds tracked by Wall St. Rank hold EDIT as of Q1 2022.

HITE Hedge Asset Management reported no remaining Editas Medicine position as of Q1 2022 after selling out during the quarter.
HITE Hedge Asset Management sold 21,046 Editas Medicine shares in Q1 2022, an estimated $559K.
HITE Hedge Asset Management first reported a position in Editas Medicine in Q2 2021 and held it in 3 quarters.
HITE Hedge Asset Management's Editas Medicine position peaked at $1.19M in Q2 2021.
256 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2022.

Based on HITE Hedge Asset Management's 13F filing for Q1 2022, filed 16 May 2022.